instem clinical limited
instem clinical limited Company Information
Company Number
06959053
Next Accounts
Sep 2025
Shareholders
instem clinical holdings ltd
Group Structure
View All
Industry
Business and domestic software development
Registered Address
diamond way stone business park, stone, staffordshire, ST15 0SD
Website
www.instem.cominstem clinical limited Estimated Valuation
Pomanda estimates the enterprise value of INSTEM CLINICAL LIMITED at £408.8k based on a Turnover of £597k and 0.68x industry multiple (adjusted for size and gross margin).
instem clinical limited Estimated Valuation
Pomanda estimates the enterprise value of INSTEM CLINICAL LIMITED at £0 based on an EBITDA of £-153k and a 4.23x industry multiple (adjusted for size and gross margin).
instem clinical limited Estimated Valuation
Pomanda estimates the enterprise value of INSTEM CLINICAL LIMITED at £0 based on Net Assets of £-2.2m and 2.37x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Instem Clinical Limited Overview
Instem Clinical Limited is a live company located in staffordshire, ST15 0SD with a Companies House number of 06959053. It operates in the business and domestic software development sector, SIC Code 62012. Founded in July 2009, it's largest shareholder is instem clinical holdings ltd with a 100% stake. Instem Clinical Limited is a established, small sized company, Pomanda has estimated its turnover at £597k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Instem Clinical Limited Health Check
Pomanda's financial health check has awarded Instem Clinical Limited a 0.5 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 8 areas for improvement. Company Health Check FAQs
0 Strong
1 Regular
8 Weak
Size
annual sales of £597k, make it smaller than the average company (£4.5m)
£597k - Instem Clinical Limited
£4.5m - Industry AVG
Growth
3 year (CAGR) sales growth of -1%, show it is growing at a slower rate (10.2%)
-1% - Instem Clinical Limited
10.2% - Industry AVG
Production
with a gross margin of 41.9%, this company has a higher cost of product (72.1%)
41.9% - Instem Clinical Limited
72.1% - Industry AVG
Profitability
an operating margin of -25.6% make it less profitable than the average company (3.4%)
-25.6% - Instem Clinical Limited
3.4% - Industry AVG
Employees
with 7 employees, this is below the industry average (42)
7 - Instem Clinical Limited
42 - Industry AVG
Pay Structure
on an average salary of £84.7k, the company has an equivalent pay structure (£72.1k)
£84.7k - Instem Clinical Limited
£72.1k - Industry AVG
Efficiency
resulting in sales per employee of £85.3k, this is less efficient (£122.4k)
£85.3k - Instem Clinical Limited
£122.4k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Instem Clinical Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Instem Clinical Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Instem Clinical Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (17 weeks)
0 weeks - Instem Clinical Limited
17 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 1224%, this is a higher level of debt than the average (62.7%)
1224% - Instem Clinical Limited
62.7% - Industry AVG
INSTEM CLINICAL LIMITED financials
Instem Clinical Limited's latest turnover from December 2023 is £597 thousand and the company has net assets of -£2.2 million. According to their latest financial statements, Instem Clinical Limited has 7 employees and maintains cash reserves of £13 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Sep 2012 | Sep 2011 | Sep 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 597,000 | 673,000 | 665,000 | 609,000 | 355,000 | 190,000 | 767,000 | 353,000 | 1,687,000 | 727,000 | 1,256,000 | 54,601 | ||
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | -153,000 | -506,000 | -234,000 | -340,000 | -257,000 | 61,305 | ||||||||
| Interest Payable | 0 | 193,000 | 19,000 | 0 | 1,000 | 1,000 | 65,000 | 0 | 0 | 0 | 0 | 0 | ||
| Interest Receivable | 94,000 | 0 | 0 | 43,000 | 151,000 | 1,000 | 1,000 | 11,000 | 0 | 0 | 0 | 0 | ||
| Pre-Tax Profit | -169,000 | -1,317,000 | -253,000 | -299,000 | -809,000 | -956,000 | 24,000 | -773,000 | 390,000 | -61,000 | 396,000 | 61,305 | ||
| Tax | -4,000 | -15,000 | 83,000 | 92,000 | 329,000 | 135,000 | 164,000 | 81,000 | -95,000 | 23,000 | -48,000 | -12,884 | ||
| Profit After Tax | -173,000 | -1,332,000 | -170,000 | -207,000 | -480,000 | -821,000 | 188,000 | -692,000 | 295,000 | -38,000 | 348,000 | 48,421 | ||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Retained Profit | -173,000 | -1,332,000 | -170,000 | -207,000 | -480,000 | -821,000 | 188,000 | -692,000 | 295,000 | -38,000 | 348,000 | 48,421 | ||
| Employee Costs | 593,000 | 630,000 | 588,000 | 636,000 | 617,000 | 587,000 | 577,000 | 813,000 | 713,000 | 471,000 | 491,000 | 327,788 | ||
| Number Of Employees | 7 | 13 | 14 | 13 | 15 | 15 | 14 | 12 | 12 | 11 | 8 | 6 | ||
| EBITDA* | -153,000 | -369,000 | -46,000 | -154,000 | -99,000 | 62,150 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Sep 2012 | Sep 2011 | Sep 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,000 | 9,000 | 47,000 | 2,000 | 3,000 | 3,000 | 9,000 | 17,000 | 20,000 | 100,000 | 1,000 | 1,069 | 1,914 | 2,085 |
| Intangible Assets | 0 | 0 | 136,000 | 323,000 | 507,000 | 954,000 | 512,000 | 181,000 | 83,000 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 9,000 | 23,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 1,000 | 9,000 | 160,000 | 325,000 | 510,000 | 957,000 | 521,000 | 198,000 | 103,000 | 100,000 | 1,000 | 1,069 | 1,914 | 2,085 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 5,000 | 6,000 | 4,000 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 13,000 | 17,000 | 27,000 | 35,000 | 60,000 | 205,000 | 579,000 | 230,000 | 356,000 | 330,000 | 49,935 | 110,502 | 68,748 |
| Group Debtors | 139,000 | 56,000 | 189,000 | 35,000 | 1,510,000 | 133,000 | 714,000 | 487,000 | 1,710,000 | 318,000 | 257,000 | 70,999 | 0 | 0 |
| Misc Debtors | 1,000 | 3,000 | 0 | 0 | 0 | 0 | 7,000 | 13,000 | 13,000 | 11,000 | 5,000 | 0 | 0 | 0 |
| Cash | 13,000 | 63,000 | 64,000 | 30,000 | 24,000 | 151,000 | 401,000 | 98,000 | 288,000 | 202,000 | 498,000 | 50,175 | 3,917 | 32,943 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 339,000 | 220,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 195,000 | 252,000 | 594,000 | 358,000 | 2,047,000 | 683,000 | 1,552,000 | 1,183,000 | 2,245,000 | 887,000 | 1,090,000 | 171,109 | 114,419 | 101,691 |
| total assets | 196,000 | 261,000 | 754,000 | 683,000 | 2,557,000 | 1,640,000 | 2,073,000 | 1,381,000 | 2,348,000 | 987,000 | 1,091,000 | 172,178 | 116,333 | 103,776 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 1,000 | 1,000 | 0 | 9,000 | 15,000 | 7,000 | 41,000 | 47,000 | 96,000 | 38,000 | 28,097 | 152,157 | 229,766 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 373,000 | 75,337 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 2,399,000 | 2,298,000 | 1,191,000 | 957,000 | 2,579,000 | 2,627,000 | 1,614,000 | 1,132,000 | 1,669,000 | 569,000 | 320,000 | 56,147 | 0 | 0 |
| total current liabilities | 2,399,000 | 2,299,000 | 1,192,000 | 957,000 | 2,588,000 | 2,642,000 | 1,621,000 | 1,173,000 | 1,716,000 | 665,000 | 731,000 | 159,581 | 152,157 | 229,766 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 21,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 500,000 | 572,000 | 662,000 | 808,000 | 668,000 | 556,000 | 30,000 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 250,000 | 286,000 | 352,000 | 404,000 | 334,000 | 278,000 | 15,000 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 2,399,000 | 2,299,000 | 1,442,000 | 1,243,000 | 2,940,000 | 3,046,000 | 1,955,000 | 1,451,000 | 1,731,000 | 665,000 | 731,000 | 159,581 | 152,157 | 229,766 |
| net assets | -2,203,000 | -2,038,000 | -688,000 | -560,000 | -383,000 | -1,406,000 | 118,000 | -70,000 | 617,000 | 322,000 | 360,000 | 12,597 | -35,824 | -125,990 |
| total shareholders funds | -2,203,000 | -2,038,000 | -688,000 | -560,000 | -383,000 | -1,406,000 | 118,000 | -70,000 | 617,000 | 322,000 | 360,000 | 12,597 | -35,824 | -125,990 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Sep 2012 | Sep 2011 | Sep 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | -153,000 | -506,000 | -234,000 | -340,000 | -257,000 | 61,305 | ||||||||
| Depreciation | 0 | 1,000 | 1,000 | 2,000 | 3,000 | 6,000 | 8,000 | 8,000 | 6,000 | 2,000 | 1,000 | 845 | 770 | 695 |
| Amortisation | 0 | 136,000 | 187,000 | 184,000 | 155,000 | 95,000 | 34,000 | 10,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -4,000 | -15,000 | 83,000 | 92,000 | 329,000 | 135,000 | 164,000 | 81,000 | -95,000 | 23,000 | -48,000 | -12,884 | ||
| Stock | 0 | 0 | 0 | 0 | 0 | -5,000 | -1,000 | 2,000 | 4,000 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 59,000 | -148,000 | 167,000 | -1,483,000 | 1,352,000 | -733,000 | -153,000 | -874,000 | 1,268,000 | 93,000 | 471,066 | 10,432 | 41,754 | 68,748 |
| Creditors | -1,000 | 0 | 1,000 | -9,000 | -6,000 | 8,000 | -34,000 | -6,000 | -49,000 | 58,000 | 9,903 | -124,060 | -77,609 | 229,766 |
| Accruals and Deferred Income | 101,000 | 1,107,000 | 234,000 | -1,643,000 | -27,000 | 1,013,000 | 482,000 | -537,000 | 1,100,000 | 249,000 | 263,853 | 56,147 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | -500,000 | -72,000 | -90,000 | -146,000 | 140,000 | 112,000 | 526,000 | 30,000 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -116,000 | 371,000 | 33,000 | -321,000 | -1,301,000 | -29,079 | ||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -373,000 | 297,663 | 75,337 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 94,000 | -193,000 | -19,000 | 43,000 | 150,000 | 0 | -64,000 | 11,000 | 0 | 0 | 0 | 0 | ||
| cash flow from financing | 102,000 | -211,000 | 23,000 | 73,000 | 1,653,000 | -703,000 | -64,000 | 16,000 | 0 | -373,000 | 297,066 | 75,337 | ||
| cash and cash equivalents | ||||||||||||||
| cash | -50,000 | -1,000 | 34,000 | 6,000 | -127,000 | -250,000 | 303,000 | -190,000 | 86,000 | -296,000 | 447,825 | 46,258 | -29,026 | 32,943 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -50,000 | -1,000 | 34,000 | 6,000 | -127,000 | -250,000 | 303,000 | -190,000 | 86,000 | -296,000 | 447,825 | 46,258 | -29,026 | 32,943 |
instem clinical limited Credit Report and Business Information
Instem Clinical Limited Competitor Analysis
Perform a competitor analysis for instem clinical limited by selecting its closest rivals, whether from the INFORMATION AND COMMUNICATION sector, other small companies, companies in ST15 area or any other competitors across 12 key performance metrics.
instem clinical limited Ownership
INSTEM CLINICAL LIMITED group structure
Instem Clinical Limited has no subsidiary companies.
Ultimate parent company
ALLERGO MED SARL
#0160763
2 parents
INSTEM CLINICAL LIMITED
06959053
instem clinical limited directors
Instem Clinical Limited currently has 2 directors. The longest serving directors include Mr Philip Reason (May 2013) and Mr Jegan Thirukailayanathan (Apr 2024).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Philip Reason | 63 years | May 2013 | - | Director | |
| Mr Jegan Thirukailayanathan | England | 44 years | Apr 2024 | - | Director |
P&L
December 2023turnover
597k
-11%
operating profit
-153k
-70%
gross margin
41.9%
-0.9%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
-2.2m
+0.08%
total assets
196k
-0.25%
cash
13k
-0.79%
net assets
Total assets minus all liabilities
instem clinical limited company details
company number
06959053
Type
Private limited with Share Capital
industry
62012 - Business and domestic software development
incorporation date
July 2009
age
16
incorporated
UK
ultimate parent company
accounts
Audit Exemption Subsidiary
last accounts submitted
December 2023
previous names
logos edc solutions ltd (August 2013)
edc investments limited (January 2010)
accountant
-
auditor
-
address
diamond way stone business park, stone, staffordshire, ST15 0SD
Bank
HSBC UK BANK PLC
Legal Advisor
-
instem clinical limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to instem clinical limited. Currently there are 1 open charges and 1 have been satisfied in the past.
instem clinical limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for INSTEM CLINICAL LIMITED. This can take several minutes, an email will notify you when this has completed.
instem clinical limited Companies House Filings - See Documents
| date | description | view/download |
|---|
